Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Free Cash Flow (2016 - 2025)

Historic Free Cash Flow for CorMedix (CRMD) over the last 13 years, with Q3 2025 value amounting to $30.4 million.

  • CorMedix's Free Cash Flow rose 32219.22% to $30.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year increase of 26499.04%. This contributed to the annual value of -$50.7 million for FY2024, which is 3096.18% down from last year.
  • Per CorMedix's latest filing, its Free Cash Flow stood at $30.4 million for Q3 2025, which was up 32219.22% from $30.0 million recorded in Q2 2025.
  • CorMedix's Free Cash Flow's 5-year high stood at $30.4 million during Q3 2025, with a 5-year trough of -$17.4 million in Q1 2024.
  • Over the past 5 years, CorMedix's median Free Cash Flow value was -$6.3 million (recorded in 2021), while the average stood at -$1.8 million.
  • Its Free Cash Flow has fluctuated over the past 5 years, first plummeted by 30837.39% in 2021, then surged by 32219.22% in 2025.
  • Quarter analysis of 5 years shows CorMedix's Free Cash Flow stood at -$6.5 million in 2021, then grew by 3.3% to -$6.3 million in 2022, then crashed by 65.65% to -$10.4 million in 2023, then skyrocketed by 45.96% to -$5.6 million in 2024, then surged by 639.63% to $30.4 million in 2025.
  • Its Free Cash Flow stands at $30.4 million for Q3 2025, versus $30.0 million for Q2 2025 and $19.7 million for Q1 2025.